Reported Earnings • Apr 28
Full year 2025 earnings released: CN¥1.07 loss per share (vs CN¥0.19 profit in FY 2024) Full year 2025 results: CN¥1.07 loss per share (down from CN¥0.19 profit in FY 2024). Revenue: CN¥789.4m (down 30% from FY 2024). Net loss: CN¥339.6m (down CN¥398.3m from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 102 percentage points per year, which is a significant difference in performance. Announcement • Apr 28
Harbin Medisan Pharmaceutical Co., Ltd., Annual General Meeting, May 19, 2026 Harbin Medisan Pharmaceutical Co., Ltd., Annual General Meeting, May 19, 2026, at 15:30 China Standard Time. Location: The Company's Meeting Room, Harbin, Heilongjiang China Announcement • Mar 31
Harbin Medisan Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026 Harbin Medisan Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026 Announcement • Dec 31
Harbin Medisan Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026 Harbin Medisan Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026 Reported Earnings • Oct 25
Third quarter 2025 earnings released: CN¥0.37 loss per share (vs CN¥0.051 profit in 3Q 2024) Third quarter 2025 results: CN¥0.37 loss per share (down from CN¥0.051 profit in 3Q 2024). Revenue: CN¥167.5m (down 47% from 3Q 2024). Net loss: CN¥116.5m (down CN¥130.8m from profit in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Announcement • Sep 30
Harbin Medisan Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Oct 25, 2025 Harbin Medisan Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025 Reported Earnings • Sep 01
Second quarter 2025 earnings released: CN¥0.20 loss per share (vs CN¥0.022 profit in 2Q 2024) Second quarter 2025 results: CN¥0.20 loss per share (down from CN¥0.022 profit in 2Q 2024). Revenue: CN¥208.1m (down 25% from 2Q 2024). Net loss: CN¥63.5m (down CN¥71.0m from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Board Change • Jul 23
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Wang Dong was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Jul 02
Harbin Medisan Pharmaceutical Co., Ltd. to Report First Half, 2025 Results on Aug 27, 2025 Harbin Medisan Pharmaceutical Co., Ltd. announced that they will report first half, 2025 results on Aug 27, 2025 Board Change • Jun 20
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Dong Wang was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. New Risk • May 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Dividend is not well covered by earnings and cash flows. Dividend per share is over 5x earnings per share. Paying a dividend despite having no free cash flows. Earnings have declined by 28% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.0% net profit margin). Declared Dividend • May 24
Dividend of CN¥0.20 announced Dividend of CN¥0.20 is the same as last year. Ex-date: 29th May 2025 Payment date: 29th May 2025 Dividend yield will be 1.3%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is not covered by earnings (dividend approximately 5x earnings) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 76 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to grow by 525% to bring the payout ratio under control. However, EPS has declined by 41% over the last 5 years so the company would need to reverse this trend. New Risk • May 02
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.0% Last year net profit margin: 4.9% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Dividend per share is over 5x earnings per share. Paying a dividend despite having no free cash flows. Earnings have declined by 28% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.0% net profit margin). Reported Earnings • Apr 26
Third quarter 2024 earnings released: EPS: CN¥0.051 (vs CN¥0.024 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.051 (up from CN¥0.024 in 3Q 2023). Revenue: CN¥315.1m (up 11% from 3Q 2023). Net income: CN¥14.3m (up 80% from 3Q 2023). Profit margin: 4.5% (up from 2.8% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Announcement • Apr 25
Harbin Medisan Pharmaceutical Co., Ltd., Annual General Meeting, May 15, 2025 Harbin Medisan Pharmaceutical Co., Ltd., Annual General Meeting, May 15, 2025, at 15:30 China Standard Time. Location: The Company's Meeting Room, Harbin, Heilongjiang China New Risk • Apr 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 112% Paying a dividend despite having no free cash flows. Earnings have declined by 25% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change). Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to CN¥12.93, the stock trades at a trailing P/E ratio of 74x. Average trailing P/E is 27x in the Pharmaceuticals industry in China. Total loss to shareholders of 9.1% over the past three years. Valuation Update With 7 Day Price Move • Apr 02
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to CN¥12.17, the stock trades at a trailing P/E ratio of 69.6x. Average trailing P/E is 30x in the Pharmaceuticals industry in China. Total loss to shareholders of 23% over the past three years. Announcement • Mar 31
Harbin Medisan Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025 Harbin Medisan Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025 Announcement • Dec 31
Harbin Medisan Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025 Harbin Medisan Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025 Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥11.84, the stock trades at a trailing P/E ratio of 67.7x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 38% over the past three years. Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: CN¥0.051 (vs CN¥0.024 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.051 (up from CN¥0.024 in 3Q 2023). Revenue: CN¥315.1m (up 11% from 3Q 2023). Net income: CN¥14.3m (up 80% from 3Q 2023). Profit margin: 4.5% (up from 2.8% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings. Announcement • Sep 30
Harbin Medisan Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024 Harbin Medisan Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to CN¥9.85, the stock trades at a trailing P/E ratio of 63.9x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 54% over the past three years. Reported Earnings • Aug 30
Second quarter 2024 earnings released: EPS: CN¥0.022 (vs CN¥0.042 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.022 (down from CN¥0.042 in 2Q 2023). Revenue: CN¥276.6m (down 6.3% from 2Q 2023). Net income: CN¥7.48m (down 43% from 2Q 2023). Profit margin: 2.7% (down from 4.4% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings. New Risk • Jul 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 116% Paying a dividend despite having no free cash flows. Earnings have declined by 22% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Announcement • Jun 29
Harbin Medisan Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Harbin Medisan Pharmaceutical Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024 Declared Dividend • May 31
Dividend increased to CN¥0.20 Dividend of CN¥0.20 is 100% higher than last year. Ex-date: 5th June 2024 Payment date: 5th June 2024 Dividend yield will be 1.9%, which is about the same as the industry average. Sustainability & Growth Dividend is not covered by earnings (116% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to grow by 29% to bring the payout ratio under control. However, EPS has declined by 23% over the last 5 years so the company would need to reverse this trend. Announcement • May 30
Harbin Medisan Pharmaceutical Co., Ltd. Announces Final Dividend of A Shares for 2023, Payable on 05 June 2024 Harbin Medisan Pharmaceutical Co., Ltd. announced final cash dividend of CNY 2.00000000 per 10 A shares for 2023. Record date: 04 June 2024. Ex-date: 05 June 2024. Payment date: 05 June 2024. Valuation Update With 7 Day Price Move • May 23
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥12.11, the stock trades at a trailing P/E ratio of 70.4x. Average trailing P/E is 30x in the Pharmaceuticals industry in China. Total loss to shareholders of 52% over the past three years. Announcement • Apr 28
Harbin Medisan Pharmaceutical Co., Ltd., Annual General Meeting, May 16, 2024 Harbin Medisan Pharmaceutical Co., Ltd., Annual General Meeting, May 16, 2024, at 15:30 China Standard Time. Location: The Company's Meeting Room, Harbin, Heilongjiang China Agenda: To consider 2023 annual report and its summary; to consider 2023 work report of the board of directors; to consider 2023 work report of the supervisory committee; to consider 2023 annual accounts report; to consider 2023 profit distribution plan; to consider 2024 remuneration plan for directors; to consider 2024 remuneration plan for supervisors; to consider Reappointment of 2024 audit firm; and to consider 2024 application for comprehensive credit line to banks and other financial institutions and provision of guarantee for wholly-owned subsidiaries. Announcement • Apr 27
Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023 Harbin Medisan Pharmaceutical Co., Ltd. proposed final Cash dividend/10 shares (tax included) of CNY2.00000000 for 2023. Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.06 (vs CN¥0.13 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.06 (down from CN¥0.13 in 1Q 2023). Revenue: CN¥246.8m (down 28% from 1Q 2023). Net income: CN¥18.8m (down 52% from 1Q 2023). Profit margin: 7.6% (down from 11% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance. New Risk • Apr 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥11.90, the stock trades at a trailing P/E ratio of 53.4x. Average trailing P/E is 27x in the Pharmaceuticals industry in China. Total loss to shareholders of 11% over the past three years. Announcement • Mar 30
Harbin Medisan Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Harbin Medisan Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 New Risk • Mar 27
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Feb 23
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥9.47, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in China. Total returns to shareholders of 21% over the past three years. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to CN¥9.47, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 25x in the Pharmaceuticals industry in China. Total returns to shareholders of 22% over the past three years. Announcement • Dec 29
Harbin Medisan Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024 Harbin Medisan Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024 Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.024 (vs CN¥0.003 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.024 (up from CN¥0.003 in 3Q 2022). Revenue: CN¥285.2m (up 11% from 3Q 2022). Net income: CN¥7.94m (up CN¥7.10m from 3Q 2022). Profit margin: 2.8% (up from 0.3% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Aug 07
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥12.59, the stock trades at a trailing P/E ratio of 55.3x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total returns to shareholders of 6.9% over the past three years. Announcement • Jul 01
Harbin Medisan Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023 Harbin Medisan Pharmaceutical Co., Ltd. announced that they will report first half, 2023 results on Aug 25, 2023 Announcement • May 19
Harbin Medisan Pharmaceutical Co., Ltd. Approves the Cash Dividend for the Year 2022 Harbin Medisan Pharmaceutical Co., Ltd. approved the cash dividend of CNY 1.00 (tax included) per 10 shares for the year 2022, at the AGM held on May 16, 2023. Board Change • Dec 01
High number of new directors Non-Independent Director Zihong Zhu was the last director to join the board, commencing their role in 2022. Announcement • Nov 29
Harbin Medisan Pharmaceutical Co., Ltd. Approves Management Appointments Harbin Medisan Pharmaceutical Co., Ltd. announced at the EGM held on November 25, 2022 that the company approved election of Zhuge Guomin, Liang Yanfei and Zhu Zihong as non-independent directors, Liu Hongquan as independent director and Zhai Yuping and Gao Lu as non-employee supervisors. Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Supervisor Huanyu Zou was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.003 (vs CN¥0.15 loss in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.003 (up from CN¥0.15 loss in 3Q 2021). Revenue: CN¥257.1m (up 10.0% from 3Q 2021). Net income: CN¥831.0k (up CN¥47.4m from 3Q 2021). Profit margin: 0.3% (up from net loss in 3Q 2021). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Reported Earnings • Aug 26
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: CN¥248.0m (up 1.8% from 2Q 2021). Net income: CN¥21.7m (down 5.7% from 2Q 2021). Profit margin: 8.7% (down from 9.4% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Announcement • Jun 08
Harbin Medisan Pharmaceutical Co., Ltd. Implements Final Cash Dividend for 2021, Payable on June 13, 2022 Harbin Medisan Pharmaceutical Co., Ltd. announced implementation of final cash dividend of CNY 3.20000000 per 10 A shares (tax included) for 2021. It will be payable on June 13, 2022. Its record and ex-dividend dates are June 10,2022 and June 13, 2022 respectively. Announcement • May 19
Harbin Medisan Pharmaceutical Co., Ltd. Approves Final Cash Dividend Proposal for 2021 Harbin Medisan Pharmaceutical Co., Ltd. at its Annual General Meeting of 2021 on 17 May 2022 approved the profit distribution for 2021. The company announced final cash dividend/10 shares (tax included) of CCNY 3.20000000. Announcement • Apr 28
Harbin Medisan Pharmaceutical Co., Ltd. Announces Final Cash Dividend Proposal for 2021 Harbin Medisan Pharmaceutical Co., Ltd. announced the profit distribution proposal for 2021. The company announced final cash dividend/10 shares (tax included) of CCNY 3.20000000. Reported Earnings • Apr 27
First quarter 2022 earnings: Revenues exceed analyst expectations First quarter 2022 results: Revenue: CN¥256.7m (up 12% from 1Q 2021). Net loss: CN¥1.17m (down 100% from profit in 1Q 2021). Revenue exceeded analyst estimates by 43%. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Board Change • Apr 27
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Supervisor Huanyu Zou was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥16.46, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 38x in the Pharmaceuticals industry in China. Total returns to shareholders of 52% over the past three years. Reported Earnings • Oct 27
Third quarter 2021 earnings released: CN¥0.15 loss per share (vs CN¥0.02 loss in 3Q 2020) The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: CN¥233.8m (down 31% from 3Q 2020). Net loss: CN¥46.5m (loss widened CN¥40.6m from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 12
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥25.84, the stock trades at a trailing P/E ratio of 13.6x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total returns to shareholders of 157% over the past three years. Reported Earnings • Aug 30
Second quarter 2021 earnings released: EPS CN¥0.076 (vs CN¥0.013 loss in 2Q 2020) The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: CN¥243.7m (down 28% from 2Q 2020). Net income: CN¥23.0m (up CN¥26.9m from 2Q 2020). Profit margin: 9.4% (up from net loss in 2Q 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 27
Investor sentiment deteriorated over the past week After last week's 19% share price decline to CN¥22.69, the stock trades at a trailing P/E ratio of 13.2x. Average trailing P/E is 30x in the Pharmaceuticals industry in China. Total returns to shareholders of 58% over the past three years. Valuation Update With 7 Day Price Move • Jun 23
Investor sentiment improved over the past week After last week's 27% share price gain to CN¥34.44, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total returns to shareholders of 104% over the past three years. Valuation Update With 7 Day Price Move • May 29
Investor sentiment improved over the past week After last week's 25% share price gain to CN¥28.83, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Total returns to shareholders of 54% over the past three years. Announcement • May 21
Harbin Medisan Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2020 Harbin Medisan Pharmaceutical Co., Ltd. approved a final cash dividend per ten shares (tax included) of CNY 0.80000000 for the year 2020. Valuation Update With 7 Day Price Move • May 04
Investor sentiment improved over the past week After last week's 33% share price gain to CN¥19.97, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total loss to shareholders of 3.5% over the past three years. Announcement • Apr 29
Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2020 Harbin Medisan Pharmaceutical Co., Ltd. proposed final cash dividend per ten shares (tax included) of CNY 0.80000000 for the year 2020. Reported Earnings • Apr 28
First quarter 2021 earnings released: EPS CN¥1.78 (vs CN¥0.10 in 1Q 2020) First quarter 2021 results: Revenue: CN¥230.2m (down 20% from 1Q 2020). Net income: CN¥563.3m (up CN¥531.3m from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 9% per year. Reported Earnings • Jan 30
Full year 2020 earnings released: EPS CN¥0.10 (vs CN¥0.57 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥1.34b (down 36% from FY 2019). Net income: CN¥29.8m (down 83% from FY 2019). Profit margin: 2.2% (down from 8.4% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Jan 13
New 90-day low: CN¥8.72 The company is down 20% from its price of CN¥10.88 on 15 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥9.17, the stock is trading at a trailing P/E ratio of 59x, down from the previous P/E ratio of 69.8x. This compares to an average P/E of 33x in the Pharmaceuticals industry in China. Total return to shareholders over the past three years is a loss of 48%. Is New 90 Day High Low • Dec 28
New 90-day low: CN¥9.23 The company is down 12% from its price of CN¥10.47 on 29 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. Is New 90 Day High Low • Oct 28
New 90-day low: CN¥10.31 The company is down 17% from its price of CN¥12.38 on 30 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 8.0% over the same period. Reported Earnings • Oct 23
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥48.6m, down 72% from the prior year. Total revenue was CN¥1.44b over the last 12 months, down 35% from the prior year. Announcement • Oct 17
Harbin Medisan Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020 Harbin Medisan Pharmaceutical Co., Ltd. announced that they will report Q3, 2020 results on Oct 23, 2020 Announcement • Aug 11
Harbin Medisan Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020 Harbin Medisan Pharmaceutical Co., Ltd. announced that they will report first half, 2020 results on Aug 27, 2020